Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19098401 | 0.86 | LMNA (0.33) | LMNASMN1; SMN2HTTKMT2AALDH1A1 | |
| SCHEMBL24713145 | 0.79 | LMNA (0.34) | LMNASMN1; SMN2HTTALDH1A1MAPT | |
| SCHEMBL19098405 | 0.79 | NCF1 (0.35) | HTTKMT2A | |
| SCHEMBL19122629 | 0.78 | CHRM3 (0.35) | SMN1; SMN2KMT2A | |
| SCHEMBL19083172 | 0.78 | SIGMAR1 (0.33) | LMNASMN1; SMN2HTTALDH1A1MAPT | |
| SCHEMBL22096795 | 0.73 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22857058 | 0.72 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2HTTALDH1A1MAPT | |
| SCHEMBL20714635 | 0.72 | — | — | |
| SCHEMBL15504870 | 0.72 | — | — | |
| SCHEMBL22778615 | 0.72 | NCF1 (0.42) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | Tabomedex Biosciences, LLC (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562909-B2 | Fused quadracyclic compounds, compositions and uses thereof | MKNK2, CYP2J2, PTGS2 | LMNA 4393/4885SMN1; SMN2 4269/4885HTT 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.